Sanofi 2Q: Dupixent's First Set Of Sales Are On Track
No surprises from Sanofi in the second quarter as sales of its flagship diabetes drug continue to fall – but a strong performance from recently launched Dupixent provided the French pharma with a refreshing reprieve in its earnings update.
You may also be interested in...
AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.
Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.
Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.